Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
11 July 2022 | Story Andre Damons | Photo Supplied
Prof Martie Smith and Prof Drik Opperman
Prof Martie Smit and Prof Dirk Opperman in the Department of Microbiology and Biochemistry filed a patent entitled “Process for the chemical modification of alkanes, fatty acids and fatty alcohols”.

Flavours and fragrances have a wide application in the food, feed, cosmetic, chemical and pharmaceutical sectors. Many flavour compounds are still produced via chemical synthesis or via extraction from plant or animal sources. However, there is increasing interest in their bio-production or the use of flavour compounds of (micro) biological origin. 

One reason for this shift is that chemical synthesis often uses environmentally unfriendly processes. Chemical synthesis usually also produces racemic mixtures with the second enantiomer, mirror image of the looked-for compound, often having undesirable organoleptic properties. Furthermore, the consumer has developed a “chemophobia”-attitude towards synthetic chemical compounds, especially when related to food and home-care products.  This applies even to nature-identical compounds – products that occur in nature but are produced via a non-natural chemical process. Products produced with the use of enzymes or microbes from “natural” substrates can be labelled “natural”. The flavour and fragrance industry thus pay higher prices for such products labelled as “natural”.  

The invention

A University of the Free State (UFS) team, led by Prof Martie Smit and Prof Dirk Opperman in the Department of Microbiology and Biochemistry are conducting exciting research in this area. They filed a patent entitled “Process for the chemical modification of alkanes, fatty acids and fatty alcohols”.  

The invention relates to a process for the enzymatic in-chain hydroxylation of C12 to C16 fatty acids, alcohols, and alkanes. Hydroxylation of C12 fatty acid and alcohol provides routes for the synthesis of “natural” δ-dodecalactone. The advantage of these routes is that they do not rely on massoia lactones. Massoia lactones are derived from the bark of Massoia trees which grow in Indonesia. Harvesting of the bark kills the trees.  

The cytochrome P450 enzymes (P450s) claimed in this patent are to the inventors’ knowledge the most regioselective enzymes described thus far that can be used for the synthesis of δ-dodecalactone from lauric acid or 1-dodecanol. The approach that the technology takes is to claim cytochrome P450 enzymes that share 70 % amino acid identity to a set of selected P450s for the regioselective hydroxylation of lauric acid and 1-dodecanol to synthesise δ-dodecalactone.

Still in early stage

The current state of development is early stage with the technology only demonstrated in the laboratory on a small scale (100-200 ml). Before the technology can be commercialised the team would need to further improve the regioselectivity and stability of the P450s and proof that the reactions can be scaled up in bioreactors. The technology will probably be delivered as an enzyme (amino acid sequence) with the desired properties. 

There are other research groups working on a synthetic biology approach for the de novo synthesis of δ-dodecalactone from glucose by genetically engineered microbes. It is still unclear how such a process will compare in terms of product yields, economics and environmental impact with the processes proposed by the UFS patent.

If the team had to partner with a commercial company, their first choice would be to work with an established flavour and fragrance company. Another possibility would be the small French flavour and fragrance company that Dr Alizé Pennec, the post-doc and co-inventor who initially discovered the unique P450 activity, is working for.

Please view the videos for more information on patents.

The Vice-Rector: Research and Internationalisation has released two new calls for applications for funding. Academic staff and researchers are encouraged to submit applications for these funds. At this stage we are not accepting projects from Research Fellows. 

The two funds are: 

1.  The Industrial Engagement Fund 
2.  The Intellectual Property Commercialisation Fund

Each fund has its own guidelines and application process. The guidelines are attached. The applications must be filled in on RIMS.

The RIMS application forms can be found through this link

For more information please click the documents below:



News Archive

Researchers focus on parrots, poultry and phage therapy
2014-10-10

Photo: en.wikipedia

Veterinary biotechnology focuses on microbial and molecular biological approaches to veterinary illnesses. The group working on veterinary biotechnology research at the University of the Free State (UFS) consists of two academic staff members, Prof Rob Bragg and Dr Charlotte Boucher, two post-doctoral fellows, Drs Chris Theron and Arina Hitzeroth, five PhD and three honours students.

The group has three research focus areas.

Dr Boucher says, “Our main focus area is infectious coryza in poultry, caused by the bacterium Avibacterium paragalliarum. The aim is the control of the disease, mainly through improvement of vaccines, understanding the immune response and improved biosecurity. A key objective is improving methods for serotyping; studying of selected surface antigens and investigating the influence recently discovered bacteriophages might have on virulence. We have co-operative projects with research groups in China, India and Israel.

“The second focus area is an expression system co-developed with the National Institute for Agronomic Research (INRA), France. The flagship project is the expression of the coat protein gene of the beak and feather disease virus, a disease affecting parrots, currently threatening the endangered Cape parrot. This system has led to the development of serological tests, currently under patenting. The application of this system has been extended to human-related diseases, with two interdisciplinary projects underway, co-working with Profs Muriel Meiring and Felicity Burt. Prof Meiring is working on diseases causing bleeding disorders, such as blood-clotting impairment, while Prof Burt is working on viral infections causing haemorrhagic (bleeding) disorders.

“We are also researching disease control in a post-antibiotic era, investigating the potential of phage-therapy by targeting and destroying pathogenic islands within a host, with reduced side-effects on the host itself.

“We have smaller projects, including an interdisciplinary project with Zoology, looking at the protein profile of amphibian (frog) secretions with the focus on antimicrobial activity, as these secretions assist with protecting amphibian skin against infections.”  


We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept